Treatment For Feline Leukemia (FeLV) And Immunodeficiency Virus (FIV) Receives License Renewal From USDA

T-Cyte Therapeutics, Inc. announced their conditional license renewal from the United States Department of Agriculture for Lymphocyte T-Cell Immunomodulator (LTCI). LTCI is the first and only approved treatment aid in the United States for cats infected with feline leukemia virus (FeLV) and immunodeficiency virus (FIV). LTCI is licensed and distributed by IMULAN BioTherapeutics; a US based veterinary immunobiology company. Conditional licenses are granted by the USDA for products which have passed safety and purity testing and where there is an emergency need or no other product available. LTCI is undergoing additional efficacy and potency studies.

More from

• Vetsure Named Business of the Year at 2025 SME National Business Awards
• Home of hope for Romania's dogs: The pioneering shelter doing things differently
• Pioneering new locum platform transforming veterinary landscape
• Key Stakeholders unite to advance helmet design for equine veterinary professionals
• Hallmarq hails transformational equine imaging technology